For example, the discovery of MET amplification in a subset of resistant EGFR-mutant lung cancers [14] has now led to promising activity of combination EGFR and MET TKIs [103] in EGFR-mutant lung cancer patients with acquired resistance due to MET amplification. This evidence concerns the gene EGFR and lung carcinoma.